Orencia (Abatacept)

Abatacept is a fusion protein that binds to CD80 and CD86 on antigen‑presenting cells, blocking their interaction with CD28 on T cells. This prevents the costimulatory signal needed for full T‑cell activation, thereby reducing the inflammatory cascade that drives autoimmune arthritis.

The dosage of Orencia is individualized by the prescribing physician based on the patient’s weight, disease severity, and response to therapy. The prescriber determines the appropriate amount and frequency of subcutaneous injections.

Safety data for abatacept in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Orencia, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Orencia belongs to the selective T‑cell costimulation modulator class, whereas many alternatives target cytokines such as TNF‑α or IL‑6. Its mechanism offers a different immunomodulatory pathway, which may be preferred in patients who have inadequate response or intolerance to other biologics.

Orencia must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temperature excursions occur, consult the supplier before use.

Orencia is given as a subcutaneous injection. The patient or a healthcare professional administers the pre‑filled syringe into the abdomen, thigh, or upper arm, following aseptic technique and the dosing schedule prescribed by the clinician.

The most serious risks include severe infections, opportunistic infections such as tuberculosis, and a potential increased incidence of malignancies. Patients should be monitored regularly for signs of infection and screened for cancer as part of routine clinical care.

Orencia is contraindicated in patients with known hypersensitivity to abatacept or any component of the formulation. It should also be avoided in individuals with active, uncontrolled infections or those receiving live vaccines.